Pembrolizumab-induced myasthenia gravis with respiratory involvement and favorable clinical outcome
Introduction: Pembrolizumab, a PD-1 checkpoint inhibitor, is a cornerstone of modern immunotherapy, enhancing T cell responses to eliminate cancer cells. However, this mechanism also predisposes patients to immune-related adverse events (IrAEs), including myasthenia gravis (MG)-like toxicity.1 Immun...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Clinical Medicine |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1470211825001599 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|